Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Low-Grade Astrocytoma Mutations in IDH1, P53, and ATRX Cooperate to Block Differentiation of Human Neural Stem Cells via Repression of SOX2.

Modrek AS, Golub D, Khan T, Bready D, Prado J, Bowman C, Deng J, Zhang G, Rocha PP, Raviram R, Lazaris C, Stafford JM, LeRoy G, Kader M, Dhaliwal J, Bayin NS, Frenster JD, Serrano J, Chiriboga L, Baitalmal R, Nanjangud G, Chi AS, Golfinos JG, Wang J, Karajannis MA, Bonneau RA, Reinberg D, Tsirigos A, Zagzag D, Snuderl M, Skok JA, Neubert TA, Placantonakis DG.

Cell Rep. 2017 Oct 31;21(5):1267-1280. doi: 10.1016/j.celrep.2017.10.009.

2.

Mutant IDH1 Cooperates with ATRX Loss to Drive the Alternative Lengthening of Telomere Phenotype in Glioma.

Mukherjee J, Johannessen TC, Ohba S, Chow TT, Jones L, Pandita A, Pieper RO.

Cancer Res. 2018 Jun 1;78(11):2966-2977. doi: 10.1158/0008-5472.CAN-17-2269. Epub 2018 Mar 15.

3.

ATRX loss in glioneuronal tumors with neuropil-like islands indicates similarity to diffuse astrocytic tumors.

Kakkar A, Nambirajan A, Kaur K, Kumar A, Mallick S, Suri V, Sarkar C, Kale SS, Garg A, Sharma MC.

J Neurooncol. 2016 Oct;130(1):63-68. Epub 2016 Jul 28.

PMID:
27469217
4.

Detection of ATRX and IDH1-R132H immunohistochemistry in the progression of 211 paired gliomas.

Cai J, Zhu P, Zhang C, Li Q, Wang Z, Li G, Wang G, Yang P, Li J, Han B, Jiang C, Sun Y, Jiang T.

Oncotarget. 2016 Mar 29;7(13):16384-95. doi: 10.18632/oncotarget.7650.

5.

Diagnostic revision of 206 adult gliomas (including 40 oligoastrocytomas) based on ATRX, IDH1/2 and 1p/19q status.

Mellai M, Annovazzi L, Senetta R, Dell'Aglio C, Mazzucco M, Cassoni P, Schiffer D.

J Neurooncol. 2017 Jan;131(2):213-222. doi: 10.1007/s11060-016-2296-5. Epub 2016 Oct 28.

PMID:
27796734
6.

DNA methylation signatures for 2016 WHO classification subtypes of diffuse gliomas.

Paul Y, Mondal B, Patil V, Somasundaram K.

Clin Epigenetics. 2017 Apr 4;9:32. doi: 10.1186/s13148-017-0331-9. eCollection 2017.

7.

ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an "integrated" diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma.

Reuss DE, Sahm F, Schrimpf D, Wiestler B, Capper D, Koelsche C, Schweizer L, Korshunov A, Jones DT, Hovestadt V, Mittelbronn M, Schittenhelm J, Herold-Mende C, Unterberg A, Platten M, Weller M, Wick W, Pfister SM, von Deimling A.

Acta Neuropathol. 2015 Jan;129(1):133-46. doi: 10.1007/s00401-014-1370-3. Epub 2014 Nov 27.

8.

Mutant IDH1 Disrupts the Mouse Subventricular Zone and Alters Brain Tumor Progression.

Pirozzi CJ, Carpenter AB, Waitkus MS, Wang CY, Zhu H, Hansen LJ, Chen LH, Greer PK, Feng J, Wang Y, Bock CB, Fan P, Spasojevic I, McLendon RE, Bigner DD, He Y, Yan H.

Mol Cancer Res. 2017 May;15(5):507-520. doi: 10.1158/1541-7786.MCR-16-0485. Epub 2017 Feb 1.

9.

Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor Decitabine.

Turcan S, Fabius AW, Borodovsky A, Pedraza A, Brennan C, Huse J, Viale A, Riggins GJ, Chan TA.

Oncotarget. 2013 Oct;4(10):1729-36.

10.

ATRX loss in adult supratentorial diffuse astrocytomas correlates with p53 over expression and IDH1 mutation and predicts better outcome in p53 accumulated patients.

Shao LW, Pan Y, Qi XL, Li YX, Ma XL, Yi WN, Zhang J, Zhong YF, Chang Q.

Histol Histopathol. 2016 Jan;31(1):103-14. doi: 10.14670/HH-11-664. Epub 2015 Sep 23.

PMID:
26395639
11.

Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations.

Liu XY, Gerges N, Korshunov A, Sabha N, Khuong-Quang DA, Fontebasso AM, Fleming A, Hadjadj D, Schwartzentruber J, Majewski J, Dong Z, Siegel P, Albrecht S, Croul S, Jones DT, Kool M, Tonjes M, Reifenberger G, Faury D, Zadeh G, Pfister S, Jabado N.

Acta Neuropathol. 2012 Nov;124(5):615-25. doi: 10.1007/s00401-012-1031-3. Epub 2012 Aug 12.

PMID:
22886134
12.

Loss of ATRX, associated with DNA methylation pattern of chromosome end, impacted biological behaviors of astrocytic tumors.

Cai J, Chen J, Zhang W, Yang P, Zhang C, Li M, Yao K, Wang H, Li Q, Jiang C, Jiang T.

Oncotarget. 2015 Jul 20;6(20):18105-15.

13.

Biphasic IDH1 phenotype in a diffusely infiltrating glioma: implications for pathogenesis, treatment and prognosis.

Odia Y, Varma H, Tsankova NM.

Clin Neuropathol. 2015 Sep-Oct;34(5):282-7. doi: 10.5414/NP300832.

PMID:
25907263
14.

ATRX immunostaining predicts IDH and H3F3A status in gliomas.

Ebrahimi A, Skardelly M, Bonzheim I, Ott I, Mühleisen H, Eckert F, Tabatabai G, Schittenhelm J.

Acta Neuropathol Commun. 2016 Jun 16;4(1):60. doi: 10.1186/s40478-016-0331-6.

15.

Prognostic significance of histological grading, p53 status, YKL-40 expression, and IDH1 mutations in pediatric high-grade gliomas.

Antonelli M, Buttarelli FR, Arcella A, Nobusawa S, Donofrio V, Oghaki H, Giangaspero F.

J Neurooncol. 2010 Sep;99(2):209-15. doi: 10.1007/s11060-010-0129-5. Epub 2010 Feb 21.

PMID:
20174854
16.

IDH mutation impairs histone demethylation and results in a block to cell differentiation.

Lu C, Ward PS, Kapoor GS, Rohle D, Turcan S, Abdel-Wahab O, Edwards CR, Khanin R, Figueroa ME, Melnick A, Wellen KE, O'Rourke DM, Berger SL, Chan TA, Levine RL, Mellinghoff IK, Thompson CB.

Nature. 2012 Feb 15;483(7390):474-8. doi: 10.1038/nature10860.

17.

Multicentric Glioma Develops via a Mutant IDH1-Independent Pathway: Immunohistochemical Study of Multicentric Glioma.

Karlowee V, Amatya VJ, Hirano H, Takayasu T, Nosaka R, Kolakshyapati M, Yoshihiro M, Takeshima Y, Sugiyama K, Arita K, Kurisu K, Yamasaki F.

Pathobiology. 2017;84(2):99-107. doi: 10.1159/000447951. Epub 2016 Aug 24.

18.

Immunohistochemical Analysis of ATRX, IDH1 and p53 in Glioblastoma and Their Correlations with Patient Survival.

Chaurasia A, Park SH, Seo JW, Park CK.

J Korean Med Sci. 2016 Aug;31(8):1208-14. doi: 10.3346/jkms.2016.31.8.1208. Epub 2016 May 30.

19.

Epigenetic silencing of XAF1 in high-grade gliomas is associated with IDH1 status and improved clinical outcome.

Reich TR, Switzeny OJ, Renovanz M, Sommer C, Kaina B, Christmann M, Tomicic MT.

Oncotarget. 2017 Feb 28;8(9):15071-15084. doi: 10.18632/oncotarget.14748.

20.

IDH mutations as an early and consistent marker in low-grade astrocytomas WHO grade II and their consecutive secondary high-grade gliomas.

Juratli TA, Kirsch M, Robel K, Soucek S, Geiger K, von Kummer R, Schackert G, Krex D.

J Neurooncol. 2012 Jul;108(3):403-10. doi: 10.1007/s11060-012-0844-1. Epub 2012 Mar 13.

PMID:
22410704

Supplemental Content

Support Center